Physician profile
Pavankumar Tandra
NPI 1477879567
$2,624.73
in general payments reported to CMS, 2019-2025
33 companies · $872 in 2025
The $872 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2023: $919 · 2024: $822 · 2025: $872.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,612.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $359.46 | 2023-2025 | Enhertu, Datroway |
| Gilead Sciences, INC. | $357.11 | 2021-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $248.42 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $240.08 | 2023-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $143.86 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $142.57 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $140.49 | 2023-2025 | Fruzaqla, Ninlaro |
| Array Biopharma INC | $129.43 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Idorsia Pharmaceuticals US INC | $125.50 | 2024 | Quviviq |
| Taiho Oncology, INC. | $98.73 | 2024-2025 | |
| Glaxosmithkline, LLC. | $75.27 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Seagen INC. | $57.13 | 2023 | Padcev, Tukysa |
| Celgene Corporation | $47.06 | 2023 | Reblozyl, Pomalyst |
| Incyte Corporation | $41.89 | 2023-2025 | Jakafi |
| Genmab U.S., INC. | $36.49 | 2023-2025 | Epkinly |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $33.66 | 2023-2025 | Cabometyx |
| Jazz Pharmaceuticals INC. | $30.84 | 2023 | |
| Genentech USA, INC. | $30.45 | 2023 | Gavreto, Alecensa, Tecentriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.09 | 2023 | Gilotrif |
| Abbvie INC. | $27.76 | 2025 | |
| Sumitomo Pharma America, INC. | $26.86 | 2023 | Orgovyx |
| Beigene USA, INC. | $25.03 | 2023 | Brukinsa |
| Dendreon Pharmaceuticals LLC | $24.81 | 2024 | Provenge |
| Astellas Pharma US INC | $24.66 | 2023 | Padcev |
| Stemline Therapeutics INC. | $22.23 | 2024 | Orserdu |
| Iovance Biotherapeutics, INC. | $20.73 | 2025 | Amtagvi |
| Kite Pharma, INC. | $20.22 | 2023 | |
| Aveo Pharmaceuticals, INC. | $16.86 | 2023 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $16.34 | 2025 | Onivyde |
| Beone Medicines USA, INC. | $13.92 | 2025 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $13.82 | 2023 | Qinlock |
| Veracyte, INC. | $4.96 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavankumar Tandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.